Percutaneous aorta bracket or aortic valve bracket system with far-end protection

Abstract

The invention relates to a percutaneous aorta bracket or an aortic valve bracket system with far-end protection, which comprises an outer sheath pipe, a limit pipe and an inner sheath pipe, wherein the inner sheath pipe is arranged in the limit pipe; the limit pipe is arranged in the outer sheath pipe; the inner sheath pipe is a hollow pipe; three handles are respectively arranged at the near ends of the inner sheath pipe, the limit pipe and the outer sheath pipe. The system further comprises a protector and a protector limiting device, wherein the protector is arranged between the far end parts of the outer sheath pipe and the inner sheath pipe; the near end of the protector is connected with the far end of the protector limiting device; the protector limiting device is arranged between the limit pipe and the outer sheath pipe; the near end of the protector limiting device is fixedly connected with the far end of the limit pipe; a retracing conducting wire is fixedly connected with the near end of the protector; the far end part of the end retracing conducting wire is arranged on the outer side of the outer sheath pipe. The system provided by the invention effectively prevents impurities such as valve leaflet tissue or atheromatous plaque touched to fall due to follow-up operations from entering into vessels such as carotid, remarkably reduces the complexity and the difficulty of the operation, and shortens the operation time and the recovery time after the operation.

Description

Technical field: [0001] The invention relates to a medical device, in particular to a percutaneous aortic stent or aortic valve stent system with distal protection. Background technique: [0002] The common valvular disease in clinic is rheumatic heart valve disease caused by rheumatic fever, followed by valvular calcification, thickening, coronary heart disease, myocardial infarction and chronic myocardial ischemia caused by arteriosclerosis and senile degeneration. Muscle fibrosis is accompanied by dysfunction. With the improvement of human living standards and the prolongation of life expectancy, the number of patients with aortic valve disease is increasing. The incidence of adult rheumatic valvular heart disease in my country is 2.34‰-2.72‰. According to the estimated population of 1.3 billion, there are about 2 million adults with rheumatic valvular heart disease. The traditional treatment method is surgical valve replacement, but its high risk and postoperative comp...

AI Technical Summary

Problems solved by technology

However, the above two systems cannot prevent the leaflet tissue shaken off due to contact between the stent and the calcified valve leaflet and the wall of the aortic cavity, or impurities such as atherosclerotic plaque on the wall of the ascending aorta from entering the carotid artery and other vessels, and the latter is precisely the One of the culprits of stroke

[0006] Patent US20100185231 discloses a treatment plan for percutaneous aortic valve replacement. In this plan, a device such as a protective umbrella is implanted in the position where the proximal end of each vessel connects to the aorta through the femoral artery or other arteries in advance, and then the valve replacement is performed. , but this two-step operation method is more complicated, the operation time is long, the difficulty is high, and the recovery time of the patient is long

[0007] In summary, the current aortic valve replacement surgery either does not have a thrombus protection device at all, resulting in serious intraoperative and postoperative thrombotic complications; or the protective umbrella is pre-implanted near the aortic arch or other vessels of interest. end, and then use different delivery catheters to implant the aortic valve stent into the target position, which is complicated, takes too long and the patient recovers poorly

Images